Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Core Viewpoint - Gain Therapeutics, Inc. is advancing the discovery and development of next-generation allosteric small molecule therapies, with a focus on treating neurodegenerative diseases, rare genetic disorders, and oncology [3][5]. Company Update - The interim-CEO and current CFO Gene Mack will host a business and corporate update call on July 1, 2024, at 8:30 am ET [1]. - Participants can access the call through the company's website, and a recorded version will be available within 24 hours after the event [2]. Drug Discovery Platform - Gain Therapeutics utilizes its Magellan™ drug discovery platform, which employs AI-supported structural biology and supercomputer-powered models to identify novel allosteric binding sites on proteins [6]. - The platform can explore vast chemical spaces of over five trillion compounds to find suitable small molecule hits for experimental validation [6]. Lead Drug Candidate - Gain's lead drug candidate, GT-02287, is currently being evaluated in a Phase 1 clinical trial for the treatment of Parkinson's disease [5].